Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
Compositions and methods are provided that are useful for diagnosing, treating, and monitoring alcohol dependence and disorders, susceptibility to alcohol dependence disorders, as well as drug related dependence and disorders. The methods include treating patients with an antagonist of the serotonin receptor 5-HT3 for such disorders, wherein the patient's serotonin transporter gene SLC6A4 is known to have particular genotypes.
1. A method of treating an alcohol-related disease or disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of ondansetron, wherein the disease or disorder is alcohol abuse or alcohol dependence and the patient's HTR3A gene and optionally serotonin transporter gene SLC6A4 and/or HTR3B gene is known to have a genotype selected from:
i. the AG genotype of rs1150226;
ii. the AG genotype of rs1150226 and the AC genotype of rs17614942;
iii. the AG genotype of rs1150226, the LL genotype of 5-HTTLPR, and the TT genotype of rs1042173; and
iv. the AG genotype of rs1150226, the AC genotype of rs17614942, the LL genotype of 5-HTTLPR, and the TT genotype of rs 1042173.
2. The method of claim 1 , wherein the patient is known to have genotype (i).
3. The method of claim 1 , wherein the patient is known to have genotype (ii).
4. The method of claim 1 , wherein the patient is known to have genotype (iii).
5. The method of claim 1 , wherein the patient is known to have genotype (iv).
6. The method of claim 1 , wherein the ondansetron is administered at a dosage ranging from 0.1 μg/kg to 1000 μg/kg per application.
7. The method of claim 1 , wherein the ondanesetron is administered at a dosage of 3.0 μg/kg per application or 4.0 μg/kg per application.
8. The method of claim 1 , wherein a response from the treatment, comprises: a reduction in drinking
9. The method of claim 1 , wherein the ondansetron is administered at a dosage of 1.0 μg/kg per application.
10. The method of claim 1 , wherein the ondansetron is administered at a dosage of 2.0 μg/kg per application.
11. The method of claim 1 , wherein the ondansetron is administered at a dosage of 3.0 μg/kg per application.
12. The method of claim 1 , wherein the ondansetron is administered at a dosage of 4.0 μg/kg per application.
13. The method of claim 1 , wherein the ondansetron is administered at a dosage of 5.0 μg/kg per application.
14. The method of claim 1 , wherein the ondansetron is administered at a dosage of 6.0 μg/kg per application.
15. The method of claim 1 , wherein the ondansetron is administered at a dosage of 7.0 μg/kg per application.
16. The method of claim 1 , wherein the ondansetron is administered at a dosage of 8.0 μg/kg per application.
17. The method of claim 1 , wherein the ondansetron is administered at a dosage of 9.0 μg/kg per application.
18. The method of claim 1 , wherein the ondansetron is administered at a dosage of 10 μg/kg per application.
19. The method of claim 1 , wherein the ondansetron is administered once a day.
20. The method of claim 1 , wherein the ondansetron is administered twice a day.
21. The method of claim 8 , wherein the reduction in drinking, comprises a reduction of heavy drinking.
22. The method of claim 8 , wherein the reduction in drinking, comprises a reduction of excessive drinking.
23. The method of claim 8 , wherein the reduction in drinking, comprises a reduction of drinks/day.
24. The method of claim 8 , wherein the reduction in drinking, comprises a reduction of drinks per drinking day.